Skip to main
HAE

Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics (HAE) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Haemonetics is a leader in the medical products and solutions industry, with innovative technologies and a strong global presence. Its two core business units, Apheresis and MedSurg, are poised for continued growth and profitability. While there have been some recent commercial execution challenges, the company is taking steps to address these and has a solid track record of successful acquisitions. With a stable Plasma business and a recovery in its IVT segment, HAE has the potential to reach best-in-class margins among its peers.

Bears say

Haemonetics is a company that operates in a competitive market, with its blood center segment facing challenges due to high competition. While the approval of Vascade MVP XL label expansion and pending FDA review for PerQseal Elite are positive developments, the company's guidance for FY27 shows only modest growth potential. With a decline in the blood center segment and a conservative outlook, Haemonetics may struggle to meet expectations, leading to a negative outlook from a financial analysis perspective.

Haemonetics (HAE) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Haemonetics (HAE) Forecast

Analysts have given Haemonetics (HAE) a Buy based on their latest research and market trends.

According to 9 analysts, Haemonetics (HAE) has a Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $81.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $81.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Haemonetics (HAE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.